[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339290-105":59,"doc-detail-339290-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-pharmacoepigenetic-paradigm-in-cancer-treatment-review","The pharmacoepigenetic paradigm in cancer treatment - Review","","Epigenetic modifications drive cancer development and progression by changing gene expression without altering DNA sequence, reshaping cellular function and gene activity. The work reviews epigenetic drugs designed to modulate epigenetic marks, including histone deacetylase, histone acetyltransferase, histone methyltransferase, and DNA methyltransferase inhibitors. It highlights ongoing research and clinical trials assessing efficacy, especially in combination regimens to improve therapeutic outcomes and address drug resistance. Additional attention is given to nutrition, inflammation control, and circadian regulation as modifiers of drug response, supporting more precise, personalized treatment strategies with potentially fewer side effects.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-pharmacoepigenetic-paradigm-in-cancer-treatment-review/339290/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-pharmacoepigenetic-paradigm-in-cancer-treatment-review/339290.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the core concept behind the pharmacoepigenetic paradigm in cancer treatment?","Question",{"text":113,"@type":114},"It focuses on using epigenetic drugs to modulate gene expression through changes in the epigenetic landscape, without changing the DNA sequence itself.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which types of epigenetic drugs are discussed?",{"text":118,"@type":114},"The review covers histone deacetylase inhibitors, histone acetyltransferase inhibitors, histone methyltransferase inhibitors, and DNA methyltransferase inhibitors.",{"name":120,"@type":111,"acceptedAnswer":121},"Why are combination therapies emphasized?",{"text":122,"@type":114},"They may target cancer more effectively and help overcome drug resistance, improving therapeutic outcomes.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},339290,1790475404,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 24 April 2024  \nDOI 10.3389/fphar.2024.1381168  \nOPEN ACCESS  \nEDITED BY  \nElixabet Lopez-Lopez,  \nUniversity of the Basque Country, Spain  \nREVIEWED BY  \nMarcella Barbarino, University of Siena, Italy Tamas Gonda,  \nNew York University, United States  \n*CORRESPONDENCE  \nAndrés López-Cortés,  [aalc84@gmail.com](aalc84@gmail.com)  \nRECEIVED 02 February 2024  \nACCEPTED 11 April 2024  \nPUBLISHED 24 April 2024  \nCITATION  \nOcaña-Paredes B, Rivera-Orellana S, Ramírez-Sánchez D, Montalvo-Guerrero J, Freire MP, Espinoza-Ferrao S,  \nAltamirano-Colina A, Echeverría-Espinoza P, Ramos-Medina MJ, Echeverría-Garcés G, Granda-Moncayo D, Jácome-Alvarado A, Andrade MG and López-Cortés A (2024), The  \npharmacoepigenetic paradigm in cancer treatment.  \nFront. Pharmacol. 15:1381168 .  \ndoi: 10.3389/fphar.2024.1381168  \nCOPYRIGHT  \n© 2024 Ocaña-Paredes, Rivera-Orellana, Ramírez-Sánchez, Montalvo-Guerrero, Freire, Espinoza-Ferrao, Altamirano-Colina, Echeverría-Espinoza, Ramos-Medina, Echeverría-Garcés, Granda-Moncayo, Jácome-Alvarado, Andrade and López-Cortés. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe pharmacoepigenetic paradigm in cancer treatment  \nBelén Ocaña-Paredes 1, Sebastián Rivera-Orellana 2, David Ramírez-Sánchez 1, Juliana Montalvo-Guerrero 1, María Paula Freire 1, Samantha Espinoza-Ferrao 1,  \nAdriana Altamirano-Colina 1, Paulina Echeverría-Espinoza 1, María José Ramos-Medina 3, Gabriela Echeverría-Garcés 4,5, Danilo Granda-Moncayo 6, Andrea Jácome-Alvarado 1, María Gabriela Andrade 1 and Andrés López-Cortés 1*  \n1Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador, 2Facultad de Ingenierías y Ciencias Aplicadas, Universidad Internacional SEK, Quito, Ecuador, 3German Cancer Research Center (DKFZ), Faculty of Biosciences, Heidelberg University, Heidelberg, Germany, 4Centro de Referencia Nacional de Genómica, Secuenciación y Bioinformática, Instituto Nacional de Investigación en Salud Pública “Leopoldo Izquieta Pérez”, Quito, Ecuador, 5Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Santiago, Chile, 6Deutsche Gesellschaft für Internationale Zusammenarbeit Gmbh, Quito, Ecuador  \nEpigenetic modiﬁcations, characterized by changes in gene expression without altering the DNA sequence, play a crucial role in the development and progression of cancer by signiﬁcantly inﬂuencing gene activity and cellular function. This insight has led to the development of a novel class of therapeutic agents, known as epigenetic drugs. These drugs, including histone deacetylase inhibitors, histone acetyltransferase inhibitors, histone methyltransferase inhibitors, and DNA methyltransferase inhibitors, aim to modulate gene expression to curb cancer growth by uniquely altering the epigenetic landscape of cancer cells. Ongoing research and clinical trials are rigorously evaluating the efﬁcacy of these drugs, particularly their ability to improve therapeutic outcomes when used in combination with other treatments. Such combination therapies may more effectively target cancer and potentially overcome the challenge of drug resistance, a signiﬁcant hurdle in cancer therapy. Additionally, the importance of nutrition, inﬂammation control, and circadian rhythm regulation in modulating drug responses has been increasingly recognized, highlighting their role as critical modiﬁers of the epigenetic landscape and thereby inﬂuencing the effectiveness of pharmacological interventions and patient outcomes. Epigenetic drugs represent a paradi","cbCaif5sxKqQLg1G","https://ap.wps.com/l/cbCaif5sxKqQLg1G","pdf",1180146,14,"English","# Introduction\n## The history of epigenetics","[{\"question\":\"What is the core concept behind the pharmacoepigenetic paradigm in cancer treatment?\",\"answer\":\"It focuses on using epigenetic drugs to modulate gene expression through changes in the epigenetic landscape, without changing the DNA sequence itself.\"},{\"question\":\"Which types of epigenetic drugs are discussed?\",\"answer\":\"The review covers histone deacetylase inhibitors, histone acetyltransferase inhibitors, histone methyltransferase inhibitors, and DNA methyltransferase inhibitors.\"},{\"question\":\"Why are combination therapies emphasized?\",\"answer\":\"They may target cancer more effectively and help overcome drug resistance, improving therapeutic outcomes.\"}]","The pharmacoepigenetic paradigm in cancer treatment - Review | PDF",1790029268,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0597ac20b2d7f917b7e94da7d2e193cb.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b42acece084a649e85bb409a4bacf36.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bcd75e31aeedb06b95ea2415db9751d1.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f1d08024b7fe14a3c21a3df6169932f.webp",980,1385]